Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis
暂无分享,去创建一个
Roberto Conti | Paolo Carminati | A. Arduini | R. Conti | E. Mannucci | Edoardo Mannucci | Arduino Arduini | P. Carminati | Pompeo Pessotto | Emanuela Tassoni | Fabio Giannessi | E. Tassoni | F. Giannessi | P. Pessotto
[1] C. Townsend,et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. , 2000, Science.
[2] J. Girard,et al. Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community. , 2001, Molecular genetics and metabolism.
[3] J. McGarry,et al. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.
[4] P. J. Randle,et al. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. , 1998, Diabetes/metabolism reviews.
[5] P. Fasching,et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. , 1991, Metabolism: clinical and experimental.
[6] L. Mandarino,et al. Mechanism of hyperglycemia and response to treatment with an inhibitor of fatty acid oxidation in a patient with insulin resistance due to antiinsulin receptor antibodies. , 1984, The Journal of clinical endocrinology and metabolism.
[7] M. Mozzoli,et al. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. , 2001, Diabetes.
[8] D. James,et al. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. , 1985, The American journal of physiology.
[9] B. Viollet,et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.
[10] R. Hanson,et al. Gluconeogenesis, its regulation in mammalian species , 1976 .
[11] R. Rizza,et al. Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.
[12] M. Rigoulet,et al. Stimulation by glucose of gluconeogenesis in hepatocytes isolated from starved rats. , 1987, The Biochemical journal.
[13] P. Lazarow. Assay of peroxisomal beta-oxidation of fatty acids. , 1981, Methods in enzymology.
[14] B. Teusink,et al. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. , 2005, Journal of lipid research.
[15] E. Newsholme,et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.
[16] J. Schölmerich,et al. Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. , 2004, American journal of physiology. Endocrinology and metabolism.
[17] H. Reinauer,et al. Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[18] J. Stoler,et al. Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation , 2004, Journal of Inherited Metabolic Disease.
[19] J. Romijn,et al. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[20] M. Lane,et al. Hypothalamic malonyl-CoA as a mediator of feeding behavior , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Häkkinen,et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.
[22] M. Bennett,et al. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. , 2004, Molecular genetics and metabolism.
[23] T P Stein,et al. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. , 2001, American journal of physiology. Endocrinology and metabolism.
[24] Roberto Conti,et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production , 2003, Nature Medicine.
[25] Gary W. Cline,et al. Glycerol-3-Phosphate Acyltransferase 1 Deficiency in ob/ob Mice Diminishes Hepatic Steatosis but Does Not Protect Against Insulin Resistance or Obesity , 2010, Diabetes.
[26] A. Arduini,et al. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity. , 2003, Journal of medicinal chemistry.
[27] R. DeFronzo,et al. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.
[28] R. Kulkarni,et al. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. , 2000, Diabetes.
[29] R. DeFronzo,et al. Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.
[30] S. Schmidt-Schweda,et al. First clinical trial with etomoxir in patients with chronic congestive heart failure. , 2000, Clinical science.
[31] B. Ljung,et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. , 2001, Diabetes.
[32] J. Foley,et al. Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. , 1995, Journal of medicinal chemistry.
[33] J. Foley,et al. Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[34] J. McGarry,et al. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. , 2001, Diabetes.
[35] M. Berry,et al. Isolated Hepatocytes: Preparation, Properties and Applications , 1991 .
[36] R. Coccurello,et al. Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice , 2010, Psychopharmacology.
[37] J. Mccormack,et al. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. , 2001, Current pharmaceutical design.
[38] J. Proietto,et al. Molecular Mechanisms of Increased Glucose Production: Identifying Potential Therapeutic Targets , 2004, Journal of Investigative Medicine.
[39] L. Rossetti,et al. Minireview: nutrient sensing and the regulation of insulin action and energy balance. , 2003, Endocrinology.
[40] S. Litwin,et al. Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. , 1990, The American journal of physiology.
[41] R. Anderson. Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? , 1970, Current pharmaceutical design.
[42] J. Romijn,et al. Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400440-JLR200 , 2005, Journal of Lipid Research.
[43] J C Stanley,et al. The glucose-fatty acid cycle. Relationship between glucose utilization in muscle, fatty acid oxidation in muscle and lipolysis in adipose tissue. , 1981, British journal of anaesthesia.